novo nordisk semaglutide Drops Hims & Hers: Inside the Compounded GLP-1 Crisis Novo Nordisk's semaglutide shows promise

Foundayo, a once-daily weight loss pill, receives FDA approval

The vial is reconstituted with bacteriostatic water before the first injection, kept refrigerated, and used within a defined window

Who Should Consider GLP-1: A Provider-Guided Framework GLP-1 therapy may be medically appropriate for individuals with BMI 30, OR BMI 2729.9 with weight-related comorbidities (hypertension, type 2 diabetes, coronary heart disease), OR lower BMI with evidence of metabolic dysfunction (prediabetes, insulin resistance, dyslipidemia)

Experimental models have shown that DSIP administration increases GABAergic activity while reducing excitatory neurotransmission in cortical and limbic regions

Journal of Sports Health and Safety